RxDoctor Payments Data

James Cobb, MD

Internal Medicine · Bogart, GANPI 1336134477

Payments from drug & device makers

$292in general payments, 2019–2025

Across 13 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$100
  • Exact Sciences$55
  • Novo Nordisk$29
  • Verona Pharma, Inc.$26
  • AstraZeneca$20
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$18
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$292 in reported general payments places this provider in the 45th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$65,776
Medicare patients
217
Services billed
851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate115$102,485
EliquisApixaban112$76,999
XareltoRivaroxaban50$39,484
JardianceEmpagliflozin52$39,232
OzempicSemaglutide27$33,814
Breo ElliptaFluticasone/Vilanterol29$15,690
MyrbetriqMirabegron19$14,610
FarxigaDapagliflozin Propanediol19$14,444
RybelsusSemaglutide12$11,435
LinzessLinaclotide19$10,061
Gabapentin517$7,689
Combivent RespimatIpratropium/Albuterol Sulfate13$7,297
Nateglinide177$6,268
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$6,150
Ondansetron Hcl35$5,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$13$102,485115 claims
Novo NordiskOzempic, Rybelsus$29$45,25039 claims
AstraZenecaFarxiga, Brilinta, Symbicort$20$23,44148 claims
AbbVieLinzess, Synthroid$100$15,61466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Bogart

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →